Multiple Sclerosis
From the Journals
Two MS diagnostic criteria found to have similar accuracy
Retrospective study of 2010 McDonald and 2016 MAGNIMS criteria indicates a need for increased specificity for MS diagnosis.
From the Journals
Rituximab may outperform some other first-line multiple sclerosis treatments
Real-world effectiveness study in Sweden found rituximab had lowest discontinuation rate of all disease-modifying treatments studied.
FDA/CDC
FDA cites manufacturer of autologous stem cells for regulatory, manufacturing missteps
American CryoStem markets the product mainly for neurologic indications.
Literature Review
MRI Reveals Lymphatic Vessels in Dura
Researchers have visualized lymphatic vessels in the dura mater of humans on MRI, according to a short report published October 3, 2017, in eLife...
Conference Coverage
Ibudilast May Slow Brain Atrophy in Progressive MS
PARIS—Ibudilast decreases the rate of brain atrophy, compared with placebo, in patients with progressive multiple sclerosis (MS), according to top...
FDA/CDC
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
Gadolinium-based contrast agents used for MRI will now carry a warning regarding potential retention in the bodies and brains of treated patients...
FDA/CDC
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
Gadolinium-based contrast agents used for MRI will now carry a warning regarding potential retention in the bodies and brains of treated patients...
Conference Coverage
Ozanimod Is Superior to Interferon in Relapsing-Remitting MS
PARIS—Ozanimod is superior to interferon beta-1a on clinical and MRI measures in patients with relapsing-remitting multiple sclerosis (MS),...
Medical Education Library
2017 MS Highlights: The Year in Review
Neurology Reviews presents selected news highlights in MS. News coverage comes from presentations at major medical meetings and from the...
Conference Coverage
Revised McDonald Criteria Allow Substitution for Dissemination in Time
PARIS—Recommended revisions to the 2010 McDonald diagnostic criteria for multiple sclerosis (MS) include changes that are intended to enable...
Conference Coverage
Durable Improvements in Clinical Outcomes With Alemtuzumab: Seven-Year Follow-Up
PARIS—Clinical efficacy of alemtuzumab was maintained for seven years in patients who had inadequate response to prior therapy, despite 47%...